Kevin Fitzgerald Selected Research

RNAi Therapeutics

1/2020	Mild iron deficiency does not ameliorate the phenotype of a murine erythropoietic protoporphyria model.
6/2019	Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis.
1/2019	An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema.
1/2017	An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.
1/2016	Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.
11/2015	Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification.
4/2015	Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.
8/2013	Safety and efficacy of RNAi therapy for transthyretin amyloidosis.
8/2008	Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kevin Fitzgerald Research Topics

Disease

7	Inflammation (Inflammations) 01/2016 - 08/2012
5	Anemia 01/2021 - 08/2012
4	Myocardial Infarction 01/2016 - 08/2010
3	Primary Hyperoxaluria (Oxaluria, Primary) 01/2022 - 01/2016
3	Iron Overload 01/2021 - 04/2015
3	beta-Thalassemia (Cooley's Anemia) 01/2021 - 04/2015
3	Thalassemia 01/2021 - 04/2015
3	Amyloidosis 01/2021 - 06/2016
3	Acute Intermittent Porphyria (Porphyria, Acute) 01/2019 - 05/2014
3	Obesity 11/2017 - 02/2012
2	Hypercholesterolemia 01/2022 - 08/2008
2	Polyneuropathies (Polyneuropathy) 01/2021 - 01/2021
2	Disease Progression 01/2021 - 03/2013
2	Hepatocellular Carcinoma (Hepatoma) 06/2020 - 03/2012
2	Neoplasms (Cancer) 06/2020 - 03/2012
2	Hyperinsulinism (Hyperinsulinemia) 01/2020 - 02/2012
2	Insulin Resistance 10/2019 - 02/2012
2	Inborn Genetic Diseases (Disease, Hereditary) 01/2019 - 03/2014
2	Body Weight (Weight, Body) 01/2019 - 08/2013
2	Fatty Liver 11/2017 - 02/2012
2	Hypertriglyceridemia 08/2017 - 02/2012
2	Heart Failure 09/2016 - 04/2014
2	Renal Insufficiency (Renal Failure) 01/2016 - 08/2012
2	Hepatic Porphyrias (Hepatic Porphyria) 11/2015 - 05/2014
2	Atherosclerotic Plaque (Atheroma) 04/2015 - 03/2013
2	Infarction (Infarctions) 04/2014 - 05/2013
1	Alzheimer Disease (Alzheimer's Disease) 10/2022
1	Hemochromatosis (Bronze Diabetes) 01/2021
1	AIDS-Related Complex (ARC) 01/2020
1	Iron Deficiencies 01/2020
1	Arthrogryposis renal dysfunction cholestasis syndrome 01/2020
1	Erythropoietic Protoporphyria 01/2020
1	Hypoglycemia (Reactive Hypoglycemia) 01/2020
1	Erythropoietic Porphyria (Congenital Erythropoietic Porphyria) 01/2020
1	Multiple Myeloma 01/2020
1	Congenital Hyperinsulinism 01/2020
1	Short Bowel Syndrome 11/2019
1	Myasthenia Gravis 06/2019
1	Porphyrias (Porphyria) 01/2019
1	Intestinal Volvulus (Volvulus) 01/2019

Drug/Important Bio-Agent (IBA)

14	Small Interfering RNA (siRNA)IBA 10/2022 - 05/2013
5	HepcidinsIBA 01/2021 - 08/2012
4	Proteins (Proteins, Gene)FDA Link 10/2022 - 03/2012
4	IronIBA 01/2021 - 04/2015
4	Prealbumin (Transthyretin)IBA 01/2021 - 08/2013
3	Amyloid (Amyloid Fibrils)IBA 10/2022 - 08/2013
3	GlobinsIBA 01/2021 - 04/2015
3	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 11/2017
3	Messenger RNA (mRNA)IBA 01/2020 - 06/2015
3	Heme (Haem)IBA 01/2019 - 05/2014
3	OxalatesIBA 01/2017 - 01/2016
3	Transcription Factors (Transcription Factor)IBA 04/2014 - 02/2012
3	LDL CholesterolIBA 01/2014 - 08/2010
2	givosiranIBA 01/2022 - 01/2019
2	Acute Hepatic PorphyriaIBA 01/2022 - 05/2014
2	AcetylgalactosamineIBA 01/2022 - 06/2019
2	patisiranIBA 01/2021 - 08/2013
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 03/2013
2	Hormones (Hormone)IBA 01/2021 - 04/2015
2	FructoseIBA 10/2019 - 11/2017
2	EnzymesIBA 11/2017 - 01/2017
2	Sterol Regulatory Element Binding Protein 1IBA 08/2017 - 02/2012
2	LipidsIBA 05/2017 - 02/2012
2	glycollate oxidaseIBA 01/2017 - 01/2016
2	Calcium OxalateIBA 01/2017 - 01/2016
2	Chemokine ReceptorsIBA 06/2015 - 05/2013
2	Apolipoproteins E (ApoE)IBA 04/2015 - 05/2013
1	Antisense OligonucleotidesIBA 01/2022
1	LigandsIBA 01/2022
1	lumasiranIBA 01/2022
1	ALN-PCSIBA 01/2022
1	OligonucleotidesIBA 01/2022
1	Transferrin Receptors (Transferrin Receptor)IBA 01/2021
1	ProteomeIBA 01/2021
1	QuinolonesIBA 06/2020
1	Phosphotransferases (Kinase)IBA 06/2020
1	Insulin (Novolin)FDA Link 01/2020
1	Glucagon (Glukagon)FDA Link 01/2020
1	LactamsIBA 01/2020
1	protoporphyrin IXIBA 01/2020
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 01/2020
1	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 01/2020
1	Ferrochelatase (Heme Synthetase)IBA 01/2020
1	AntibodiesIBA 01/2020
1	Ethylnitrosourea (N-Ethyl-N-nitrosourea)IBA 01/2020
1	CateninsIBA 01/2020
1	Surface Antigens (Surface Antigen)IBA 01/2020
1	Lysine (L-Lysine)FDA Link 01/2020
1	Dietary SugarsIBA 10/2019
1	Complement System Proteins (Complement)IBA 06/2019
1	Factor XII (Hageman Factor)IBA 01/2019
1	PorphobilinogenIBA 01/2019
1	BradykininIBA 01/2019
1	Aminolevulinic Acid (Levulan)FDA Link 01/2019

Therapy/Procedure

11	Therapeutics 01/2022 - 03/2013
9	RNAi Therapeutics 01/2020 - 08/2008
3	Parenteral Nutrition 11/2019 - 05/2017
2	Ligation 09/2016 - 04/2014
1	Injections 01/2019
1	Subcutaneous Injections 01/2019